CLOSED
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-ac. Track Mankind Pharma Limited's live NSE:MANKIND share price ₹2,483.00 (+0.44%), market cap ₹₹1.03T, P/E 50.3. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for MANKIND — real-time NSE India stock intelligence.
Open
₹2,458.00
High
₹2,497.90
Low
₹2,442.20
Prev. Close
₹2,472.00
52W High
₹2,674.00
52W Low
₹1,909.70
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-ac
Key Takeaway
Mankind Pharma Limited is rated buy with a P/E of 50.3x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Mankind Pharma Limited fairly valued right now?
Because a P/E of 50.3x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Mankind Pharma Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
4,031 Cr
Revenue
568 Cr
Net Profit
0%
ROE
0%
ROCE
49.39
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 8,749 | 10,259 | 12,207 | 14,278 | 14,611 |
| Net Profit | 1,282 | 1,913 | 1,991 | 1,913 | 1,969 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | 49.39 | 49.39 |
| Debt/Equity | — | — | — | 38.1 | 38.1 |